Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-8000 plus nivolumab versus placebo plus nivolumab in previously PD-1/PD-L1 inhibitor-naive unresectable or metastatic melanoma
2024-516914-39-00Phase 3Authorised
- Sponsor
- HUYABIO International, LLC
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Tucidinostat + nivolumab with Placebo + nivolumab (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2022; status: authorised.
02
Drugs
tucidinostatnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-516914-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516914-39-00.